[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07362017":3,"trial-entities:NCT07362017":100,"trial-summary:NCT07362017":104},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":23,"primary_purpose":24,"phases":25,"enrollment_info":27,"interventions":30,"primary_outcomes":36,"secondary_outcomes":41,"sex":42,"minimum_age":43,"maximum_age":44,"healthy_volunteers":15,"eligibility_criteria":45,"std_ages":57,"locations":60,"central_contacts":91,"overall_officials":97,"references":98,"see_also_links":99},"NCT07362017","VP-VSP-128-3102","Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis","A Multicenter, Open Label Study to Investigate the Safety and Efficacy of Ponesimod in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis","RECRUITING","2028-12","2026-06","2026-06-11","2026-02-17","Vanda Pharmaceuticals","INDUSTRY",false,"An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis",null,[19],"Moderate-to-severe Chronic Plaque Psoriasis",[21,22],"psoriasis","Moderate-to-severe chronic plaque psoriasis","INTERVENTIONAL","TREATMENT",[26],"PHASE3",{"count":28,"type":29},300,"ESTIMATED",[31],{"type":32,"name":33,"description":34,"armGroupLabels":35},"DRUG","Ponesimod","Oral Tablet",[33],[37],{"measure":38,"description":39,"timeFrame":40},"Safety and tolerability of ponesimod as measured by reporting of adverse events (AEs)","Safety will be assessed based on frequency of treatment-emergent adverse events and serious adverse events, and frequency of clinically notable abnormal vital signs, blood chemistry, hematology, urology, and ECGs","Through study completion, approximately 1 year",[],"ALL","18 Years","65 Years",{"inclusion":46,"exclusion":53,"raw_text":56},[47,48,49,50,51,52],"Male and female subjects aged 18-65 years, inclusive","BMI \\>18 and \\\u003C40","Minimum affected BSA of 10%","PASI score ≥ 12","PGA ≥ 3","Diagnosed with moderate-to-severe plaque psoriasis",[54,55],"Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis","History of an allergic reaction or known and\u002For significant sensitivity to study drug","Inclusion Criteria:\n\n* Male and female subjects aged 18-65 years, inclusive\n* BMI \\>18 and \\\u003C40\n* Minimum affected BSA of 10%\n* PASI score ≥ 12\n* PGA ≥ 3\n* Diagnosed with moderate-to-severe plaque psoriasis\n\nExclusion Criteria:\n\n* Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis\n* History of an allergic reaction or known and\u002For significant sensitivity to study drug",[58,59],"ADULT","OLDER_ADULT",[61,70,77,84],{"facility":62,"status":8,"city":63,"state":64,"zip":65,"country":66,"geoPoint":67},"Vanda Investigational Site","Glendale","Arizona","85308","United States",{"lat":68,"lon":69},33.53865,-112.18599,{"facility":62,"status":8,"city":71,"state":72,"zip":73,"country":66,"geoPoint":74},"Fremont","California","94538",{"lat":75,"lon":76},37.54827,-121.98857,{"facility":62,"status":8,"city":78,"state":79,"zip":80,"country":66,"geoPoint":81},"Rochester","New York","14623",{"lat":82,"lon":83},43.15478,-77.61556,{"facility":62,"status":8,"city":85,"state":86,"zip":87,"country":66,"geoPoint":88},"Spokane","Washington","99202",{"lat":89,"lon":90},47.65966,-117.42908,[92],{"name":93,"role":94,"phone":95,"email":96},"Vanda Pharmaceuticals, Inc.","CONTACT","202-734-3400","clinicaltrials@vandapharma.com",[],[],[],{"nct_id":4,"conditions":101,"biomarkers":103},[102],"Chronic small plaque psoriasis",[],{"nct_id":4,"found":15,"summary":17,"prompt_version":17}]